Kairos Pharma, Ltd.
KAPA · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1,272 | $93 | $437 | $73 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2,897 | $8 | $0 | $0 |
| Total Curr. Assets | $4,169 | $101 | $437 | $73 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $222 | $382 | $542 | $702 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $448 | $0 | $0 | $0 |
| Other NC Assets | $1,377 | $482 | $57 | $0 |
| Total NC Assets | $2,047 | $864 | $599 | $702 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $6,216 | $965 | $1,036 | $775 |
| Liabilities | – | – | – | – |
| Payables | $0 | $2,401 | $1,629 | $1,548 |
| Short-Term Debt | $0 | $0 | $4 | $380 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $992 | $4 | $0 | $14 |
| Total Curr. Liab. | $992 | $2,405 | $1,633 | $1,942 |
| LT Debt | $0 | $638 | $582 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $448 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $448 | $638 | $582 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,440 | $3,043 | $2,215 | $1,942 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $14 | $11 | $10 | $10 |
| Retained Earnings | -$8,815 | -$6,212 | -$4,400 | -$3,350 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $13,577 | $4,123 | $3,211 | $2,173 |
| Total Equity | $4,776 | -$2,078 | -$1,179 | -$1,167 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $6,216 | $965 | $1,036 | $775 |
| Net Debt | -$1,272 | $545 | $149 | $307 |